JS Link, Inc.
KOSDAQ-listed genomics company offering the EGIS genome analysis and DNAGPS personal genome services, also active in forensic identification projects.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2000 and listed on KOSDAQ in 2011, JS Link specializes in genome analysis services. It offers EGIS, a genome analysis service for researchers, and DNAGPS, a personal genome analysis service for the general public, alongside a biobank for storing human-derived biological materials and AccuID, a forensic personal identification service. Personal genome analysis allows direct-to-consumer (DTC) service for 12 items designated on June 30, 2016; its biobank partners with health checkup centers at four general hospitals; and AccuID has participated in projects such as the 2018 Jeju April 3 incident remains-excavation project.
Products & technology
- EGISGenome analysis service for researchers
- DNAGPSPersonal genome analysis service for the general public predicting disease risk
- BiobankStorage and quality control of human-derived biological materials
- AccuIDForensic personal identification service
R&D and key agreements
Source: DART corporate disclosure유전체 대량분석기술 및 한국인 유전정보 DB구축 · 20여년 연구개발, 다수 논문·특허 출원 · Some R&D outcomes have been commercialized as the EGIS product
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition